IPP Bureau
.png "Pfizer announces Talzenna and Xtandi combination data from phase 3 study")
Pfizer announces Talzenna and Xtandi combination data from phase 3 study
By IPP Bureau - February 18, 2023
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Asahi Kasei completes construction of microcrystalline cellulose plant
By IPP Bureau - February 18, 2023
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
Patient care is an imperative dimension in providing quality healthcare: Dr. Bharati Pravin Pawar
By IPP Bureau - February 18, 2023
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
Dr. Mandaviya hails eSanjeevani milestone of providing telemedicine services to 10 Cr patients
By IPP Bureau - February 18, 2023
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg
By IPP Bureau - February 18, 2023
Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)
Lupin receives EIR from USFDA for injectable facility in Nagpur
By IPP Bureau - February 18, 2023
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg
By IPP Bureau - February 18, 2023
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
By IPP Bureau - February 18, 2023
Themis will market this drug with the brand name REMITHEM.
AstraZeneca Pharma India receives no objection for Durvalumab
By IPP Bureau - February 17, 2023
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
Biocon Q3 FY23 revenue up 36%
By IPP Bureau - February 17, 2023
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData
By IPP Bureau - February 17, 2023
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
GUERISON enters Indian Ophthalmology market
By IPP Bureau - February 17, 2023
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
Briefs: Piramal Pharma, Alembic Pharmaceuticals
By IPP Bureau - February 17, 2023
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
Shilpa Medicare Unit VI Bengaluru facility registered with Ministry of Health, UAE
By IPP Bureau - February 17, 2023
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Lonza completes expansion of conjugation facility in Visp
By IPP Bureau - February 17, 2023
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
